Metsera (NASDAQ:MTSR) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Metsera (NASDAQ:MTSR - Free Report) in a research note issued to investors on Tuesday morning, MarketBeat reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Metsera's FY2025 earnings at ($3.38) EPS.

Other research analysts have also recently issued reports about the stock. Guggenheim started coverage on shares of Metsera in a report on Tuesday. They issued a "buy" rating and a $56.00 target price for the company. Bank of America initiated coverage on shares of Metsera in a report on Tuesday. They issued a "buy" rating and a $38.00 price objective for the company. Finally, Evercore ISI began coverage on Metsera in a research report on Tuesday. They issued an "outperform" rating on the stock.

Metsera Stock Down 0.9 %

Shares of MTSR traded down $0.23 during trading hours on Tuesday, hitting $24.78. The company had a trading volume of 632,299 shares, compared to its average volume of 615,395. Metsera has a 52-week low of $24.19 and a 52-week high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.